Breaking News, Financial News

Financial Report: Roche

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche FY Revenues: $42.2 billion (+10%) FY Earnings: $8.9 billion (+25%) Comments: Pharmaceutical sales were up 10% to $32.7 billion. Earnings growth was driven by sales of cancer drugs, MabThera (+15%) to $4.9 billion, as well as Herceptin and Avastin. Rituxan sales reached $5.1 billion for the year. Tamiflu sales were down 19% to $1.9 billion. Pharmaceutical R&D expenses were $6.7 billion for the year (+15%)....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters